• Dyne Therapeutics initiated the Phase 3 FORZETTO trial of z-rostudirsen for Duchenne muscular dystrophy patients eligible for exon 51 skipping, positioning the study as the confirmatory program for a planned U.S. accelerated-approval filing later this quarter.
• Prior trial results have already been presented, with the company pointing to earlier-stage data showing functional improvement signals versus placebo alongside a favorable safety profile.
• The new study is designed to test whether treatment translates into clearer mobility benefits over a 72-week, placebo-controlled period, with additional readouts intended to support broader regulatory filings outside the U.S.
• Trial design details will be presented in the future at the International Congress on Neuromuscular Diseases on July 8, 2026.
• Enrollment is set at about 90 ambulatory males ages 4 to 18, randomized 1:1 to intravenous dosing every four weeks, with an open-label extension planned for longer-term follow-up.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605200746PRIMZONEFULLFEED9723858) on May 20, 2026, and is solely responsible for the information contained therein.